Kotobuki Pharmaceutical Co., Ltd.

Astellas Pharma Inc. has moved further ahead of its rival Japanese firm Daiichi Sankyo Co. Ltd. in the acute myeloid leukaemia (AML) space after European regulators recommended its FLT3 inhibitor X

No fewer than 68 new active substances were launched in their first markets in 2018, making it the most productive year for pharma and biotech this century, new research from Pharmaprojects shows. The

The US FDA bracketed the Thanksgiving holiday with two new molecular entity approvals (NMEs) in oncology – Pfizer Inc. ’s Daurismo (glasdegib) on Nov. 21 and Loxo Oncology Inc. and Bayer AG ’s

Astellas Pharma Inc. ’s Xospata (gilteritinib) has received its first approval globally, in Japan for FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML), marking the first co